Ebola and Marburg virus matrix layers are locally ordered assemblies of VP40 dimers

  1. William Wan
  2. Mairi Clarke
  3. Michael J Norris
  4. Larissa Kolesnikova
  5. Alexander Koehler
  6. Zachary A Bornholdt
  7. Stephan Becker
  8. Erica Ollman-Saphire
  9. John AG Briggs  Is a corresponding author
  1. Vanderbilt University, United States
  2. EMBL, Germany
  3. La Jolla Institute of Immunology, United States
  4. Philipps-Universität Marburg, Germany
  5. Scripps Research Institute, United States
  6. La Jolla Institute for Immunology, United States
  7. MRC-LMB, United Kingdom

Abstract

Filoviruses such as Ebola and Marburg virus bud from the host membrane as enveloped virions. This process is achieved by the matrix protein VP40. When expressed alone, VP40 induces budding of filamentous virus-like particles, suggesting that localization to the plasma membrane, oligomerization into a matrix layer, and generation of membrane curvature are intrinsic properties of VP40. There has been no direct information on the structure of VP40 matrix layers within viruses or virus-like particles. We present structures of Ebola and Marburg VP40 matrix layers in intact virus-like particles, and within intact Marburg viruses. VP40 dimers assemble extended chains via C-terminal domain interactions. These chains stack to form 2D matrix lattices below the membrane surface. These lattices form a patchwork assembly across the membrane and suggesting that assembly may begin at multiple points. Our observations define the structure and arrangement of the matrix protein layer that mediates formation of filovirus particles.

Data availability

EM maps of VP40 from Ebola NP-VP24-VP35-VP40, VP40, VP40-GP VLPs and Marburg virions and VP40 VLPs were deposited in the EMDB with accession numbers EMD-11660, EMD-11661, EMD-11662, EMD-11663, EMD-11664, respectively. EM map of Ebola GP was deposited as EMD-11665. Crystal structures of eVP40 P62 and eVP40 P6422 were deposited to the PDB with accession numbers 7JZJ and 7JZT, respectively.

The following data sets were generated

Article and author information

Author details

  1. William Wan

    Department of Biochemistry, Vanderbilt University, Nashville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2497-3010
  2. Mairi Clarke

    Structural and Computational Biology, EMBL, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9658-4308
  3. Michael J Norris

    La Jolla Institute of Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Larissa Kolesnikova

    Institute of Virology; German Center for Infection Research (DZIF) Gießen-Marburg-Langen Site, Philipps-Universität Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Alexander Koehler

    Institute of Virology; German Center for Infection Research (DZIF) Gießen-Marburg-Langen Site, Philipps-Universität Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Zachary A Bornholdt

    Scripps Research Institute, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7557-9219
  7. Stephan Becker

    Institute of Virology; German Center for Infection Research (DZIF) Gießen-Marburg-Langen Site, Philipps-Universität Marburg, Marburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Erica Ollman-Saphire

    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. John AG Briggs

    Structural Studies, MRC-LMB, Cambridge, United Kingdom
    For correspondence
    jbriggs@mrc-lmb.cam.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3990-6910

Funding

Medical Research Council (MC_UP_1201/16)

  • John AG Briggs

H2020 European Research Council (ERC-CoG-648432)

  • John AG Briggs

Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 1021)

  • Stephan Becker

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Wan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,925
    views
  • 352
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. William Wan
  2. Mairi Clarke
  3. Michael J Norris
  4. Larissa Kolesnikova
  5. Alexander Koehler
  6. Zachary A Bornholdt
  7. Stephan Becker
  8. Erica Ollman-Saphire
  9. John AG Briggs
(2020)
Ebola and Marburg virus matrix layers are locally ordered assemblies of VP40 dimers
eLife 9:e59225.
https://doi.org/10.7554/eLife.59225

Share this article

https://doi.org/10.7554/eLife.59225

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    Berit Siedentop, Viacheslav N Kachalov ... Sebastian Bonhoeffer
    Research Article

    Background:

    Under which conditions antibiotic combination therapy decelerates rather than accelerates resistance evolution is not well understood. We examined the effect of combining antibiotics on within-patient resistance development across various bacterial pathogens and antibiotics.

    Methods:

    We searched CENTRAL, EMBASE, and PubMed for (quasi)-randomised controlled trials (RCTs) published from database inception to 24 November 2022. Trials comparing antibiotic treatments with different numbers of antibiotics were included. Patients were considered to have acquired resistance if, at the follow-up culture, a resistant bacterium (as defined by the study authors) was detected that had not been present in the baseline culture. We combined results using a random effects model and performed meta-regression and stratified analyses. The trials’ risk of bias was assessed with the Cochrane tool.

    Results:

    42 trials were eligible and 29, including 5054 patients, qualified for statistical analysis. In most trials, resistance development was not the primary outcome and studies lacked power. The combined odds ratio for the acquisition of resistance comparing the group with the higher number of antibiotics with the comparison group was 1.23 (95% CI 0.68–2.25), with substantial between-study heterogeneity (I2=77%). We identified tentative evidence for potential beneficial or detrimental effects of antibiotic combination therapy for specific pathogens or medical conditions.

    Conclusions:

    The evidence for combining a higher number of antibiotics compared to fewer from RCTs is scarce and overall compatible with both benefit or harm. Trials powered to detect differences in resistance development or well-designed observational studies are required to clarify the impact of combination therapy on resistance.

    Funding:

    Support from the Swiss National Science Foundation (grant 310030B_176401 (SB, BS, CW), grant 32FP30-174281 (ME), grant 324730_207957 (RDK)) and from the National Institute of Allergy and Infectious Diseases (NIAID, cooperative agreement AI069924 (ME)) is gratefully acknowledged.

    1. Microbiology and Infectious Disease
    Dipasree Hajra, Raju S Rajmani ... Dipshikha Chakravortty
    Research Article

    Sirtuins are the major players in host immunometabolic regulation. However, the role of sirtuins in the modulation of the immune metabolism pertaining to salmonellosis is largely unknown. Here, our investigation focussed on the role of two important sirtuins, SIRT1 and SIRT3, shedding light on their impact on intracellular Salmonella’s metabolic switch and pathogenesis establishment. Our study indicated the ability of the live Salmonella Typhimurium to differentially regulate the levels of SIRT1 and SIRT3 for maintaining the high glycolytic metabolism and low fatty acid metabolism in Salmonella. Perturbing SIRT1 or SIRT3 through knockdown or inhibition resulted in a remarkable shift in the host metabolism to low fatty acid oxidation and high glycolysis. This switch led to decreased proliferation of Salmonella in the macrophages. Further, Salmonella-induced higher levels of SIRT1 and SIRT3 led to a skewed polarization state of the macrophages from a pro-inflammatory M1 state toward an immunosuppressive M2, making it more conducive for the intracellular life of Salmonella. Alongside, governing immunological functions by modulating p65 NF-κB acetylation, SIRT1, and SIRT3 also skew Salmonella-induced host metabolic switch by regulating the acetylation status of HIF-1α and PDHA1. Interestingly, though knockdown of SIRT1/3 attenuated Salmonella proliferation in macrophages, in in vivo mice model of infection, inhibition or knockdown of SIRT1/3 led to more dissemination and higher organ burden, which can be attributed to enhanced ROS and IL-6 production. Our study hence reports for the first time that Salmonella modulates SIRT1/3 levels to maintain its own metabolism for successful pathogenesis.